A Phase 1 interventional study of Clopidogrel and Clopidogrel and Lansoprazole in Healthy, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-02-03.
Sponsored by Takeda · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Stomach Ulcer by Takeda — none open to participants now, none under way, none of them phase 3. Stomach Ulcer · Takeda.
Among the 14 studies in Stomach Ulcer by Takeda, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2009, is the only one in phase 1, and was the 4th registered.
116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.
Browse Stomach Ulcer studies →None of the 14 studies in Stomach Ulcer by Takeda is open now. The open studies under Stomach Ulcer, anywhere →
Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 160 is below the median of 298 across 88 interventional studies indexed under Stomach Ulcer.
Median enrollment 423 across the 12 interventional studies, 2,152 across the 2 observational. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Stomach Ulcer by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the potential effect and safety of multiple oral doses of dexlansoprazole, lansoprazole, omeprazole or esomeprazole, once daily (QD), on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel, and to assess the safety of multiple doses of clopidogrel in healthy participants.
This is a Phase 1, randomized, open-label, single-center, multiple-dose, 2-period, crossover study to assess the effects of multiple oral doses of dexlansoprazole, lansoprazole, omeprazole or esomeprazole on the steady-state pharmacokinetics (PK) and pharmacodynamics (PD) of clopidogrel in healthy participants.
Participants were randomized equally into eight regimen sequence groups, 20 participants each. Participants randomized to Sequence Groups 1 and 2, 3 and 4, 5 and 6 and 7 and 8 were called proton pump inhibitor (PPI) Groups 1, 2, 3, and 4, respectively. Each sequence group consists of 2 regimens. Sequence Groups 1, 3, 5 and 7 dosed Regimen A (75 mg clopidogrel) for Days 1-9 of Period 1 and then crossed over to one of the following 4 regimens for Days 1-9 of Period 2: Regimen B (75 mg clopidogrel + 30 mg lansoprazole), Regimen C (75 mg clopidogrel + 60 mg dexlansoprazole), Regimen D (75 mg clopidogrel + 80 mg [2x40 mg] omeprazole), or Regimen E (75 mg clopidogrel + 40 mg esomeprazole). Sequence Groups 2, 4, 6 and 8 began with either Regimen B, C, D or E for Period 1 and then crossed over to Regimen A for Period 2.
On Day 9 of each period, blood samples were collected at predose and for 24 hours postdose to measure plasma concentrations of the active metabolite of clopidogrel. Platelet function was assessed daily prior to the dose of clopidogrel on Days 7-9 and 24-hours post Day 9 dose in each period. There was a washout interval of 10 to 14 days between the last dose of study drug in Period 1 and the first dose of study drug in Period 2.
Study participants were confined to the study center for 10 consecutive nights in Period 1, followed by a 10- to 14-day washout interval and confined for an additional 10 consecutive nights in Period 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clopidogrel 75 mg QD
Drug: Clopidogrel
Clopidogrel 75 mg QD and Lansoprazole 30 mg QD
Drug: Clopidogrel and Lansoprazole
Clopidogrel 75 mg QD and Dexlansoprazole 60 mg QD
Drug: Clopidogrel and Dexlansoprazole
Clopidogrel 75 mg QD and Omeprazole 80 mg QD
Drug: Clopidogrel and Omeprazole
Clopidogrel 75 mg QD and Esomeprazole 40 mg QD
Drug: Clopidogrel and Esomeprazole
Clopidogrel 75 mg, tablets, orally, once daily days 1-9.
Also known as: Plavix
Drug pages: Clopidogrel · Lansoprazole
Clopidogrel 75 mg, tablets, orally, once daily and Lansoprazole 30 mg, capsules, orally, once daily days 1-9.
Also known as: Plavix, Prevacid, AG-1749
Drug pages: Clopidogrel · Dexlansoprazole
Clopidogrel 75 mg, tablets, orally, once daily and Dexlansoprazole 60 mg, capsules, orally, once daily days 1-9.
Also known as: Plavix, Kapidex, TAK-390MR
Drug pages: Clopidogrel · Omeprazole
Clopidogrel 75 mg, tablets, orally, once daily and Omeprazole 80 mg, capsules, orally, once daily days 1-9.
Also known as: Plavix
Drug pages: Clopidogrel · Esomeprazole
Clopidogrel 75 mg, tablets, orally, once daily and Esomeprazole 40 mg, capsules, orally, once daily days 1-9.
Also known as: Plavix, Nexium
Pharmacokinetic Parameter Peak Plasma Concentration (Cmax) of Clopidogrel's Active Metabolite.
Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
Time frame: Day 9 of each period
Pharmacokinetic Parameter Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]) of Clopidogrel's Active Metabolite.
Area under the plasma concentration versus time curve (AUC(0-tlqc)) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC\[0-tlqc\]).
Time frame: Day 9 of each period
Pharmacodynamic Parameter Platelet Reactivity Index (PRI) From Vasodilator-stimulated Phosphoprotein (VASP) Phosphorylation State (Flow Cytometry).
PRI is the platelet reactivity index from VASP phosphorylation state (flow cytometry).
Time frame: 24-hour post Day 9 dose in each period.
Pharmacodynamic Parameter Maximum Platelet Aggregation (MPA) From Aggregometry (Turbidimetric) With 5 µM Adenosine Diphosphate.
Maximum platelet aggregation (MPA) from aggregometry (turbidimetric) with 5 µM adenosine diphosphate.
Time frame: 24-hour post Day 9 dose in each period.
Pharmacodynamic Parameter MPA From Aggregometry (Turbidimetric) With 20 µM Adenosine Diphosphate.
MPA from aggregometry (turbidimetric) with 20 µM adenosine diphosphate.
Time frame: 24-hour post Day 9 dose in each period.
Participants enrolled at one site in the United States from 15 December 2009 to 08 July 2010.
| Milestone | PPI Group 1 | PPI Group 2 | PPI Group 3 | PPI Group 4 |
|---|---|---|---|---|
| Started | 40 | 40 | 40 | 40 |
| Completed | 38 | 36 | 38 | 38 |
| Not completed | 2 | 4 | 2 | 2 |
| Withdrew: Adverse event | 2 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 2 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 |
| Withdrew: Elevated alanine amino transferase | 0 | 0 | 0 | 1 |
| Withdrew: Low platelet count | 0 | 2 | 0 | 0 |
Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
| ng/mL | PPI Group 1: Regimen A | PPI Group 1: Regimen B | PPI Group 2: Regimen A | PPI Group 2: Regimen C | PPI Group 3: Regimen A | PPI Group 3: Regimen D | PPI Group 4: Regimen A | PPI Group 4: Regimen E |
|---|---|---|---|---|---|---|---|---|
| Pharmacokinetic Parameter Peak Plasma Concentration (Cmax) of Clopidogrel's Active Metabolite. | 39.14 ± 12.553 | 30.01 ± 15.264 | 38.85 ± 15.699 | 29.33 ± 12.400 | 38.25 ± 12.461 | 22.55 ± 10.682 | 40.98 ± 22.908 | 24.69 ± 10.641 |
Area under the plasma concentration versus time curve (AUC(0-tlqc)) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC\[0-tlqc\]).
| ng*hr/ML | PPI Group 1: Regimen A | PPI Group 1: Regimen B | PPI Group 2: Regimen A | PPI Group 2: Regimen C | PPI Group 3: Regimen A | PPI Group 3: Regimen D | PPI Group 4: Regimen A | PPI Group 4: Regimen E |
|---|---|---|---|---|---|---|---|---|
| Pharmacokinetic Parameter Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]) of Clopidogrel's Active Metabolite. | 41.69 ± 10.020 | 36.42 ± 10.825 | 41.25 ± 14.690 | 37.75 ± 13.132 | 37.78 ± 12.043 | 26.28 ± 8.800 | 42.35 ± 18.785 | 31.23 ± 9.938 |
PRI is the platelet reactivity index from VASP phosphorylation state (flow cytometry).
| percent inhibition | PPI Group 1: Regimen A | PPI Group 1: Regimen B | PPI Group 2: Regimen A | PPI Group 2: Regimen C | PPI Group 3: Regimen A | PPI Group 3: Regimen D | PPI Group 4: Regimen A | PPI Group 4: Regimen E |
|---|---|---|---|---|---|---|---|---|
| Pharmacodynamic Parameter Platelet Reactivity Index (PRI) From Vasodilator-stimulated Phosphoprotein (VASP) Phosphorylation State (Flow Cytometry). | 42.3 ± 14.61 | 46.4 ± 16.44 | 41.3 ± 15.45 | 43.0 ± 16.47 | 47.9 ± 15.70 | 59.1 ± 17.87 | 46.5 ± 17.28 | 58.0 ± 14.64 |
Maximum platelet aggregation (MPA) from aggregometry (turbidimetric) with 5 µM adenosine diphosphate.
| percentage of MPA | PPI Group 1: Regimen A | PPI Group 1: Regimen B | PPI Group 2: Regimen A | PPI Group 2: Regimen C | PPI Group 3: Regimen A | PPI Group 3: Regimen D | PPI Group 4: Regimen A | PPI Group 4: Regimen E |
|---|---|---|---|---|---|---|---|---|
| Pharmacodynamic Parameter Maximum Platelet Aggregation (MPA) From Aggregometry (Turbidimetric) With 5 µM Adenosine Diphosphate. | 28.1 ± 6.76 | 30.8 ± 9.35 | 34.6 ± 14.23 | 36.2 ± 16.87 | 34.2 ± 12.32 | 42.5 ± 14.74 | 29.3 ± 10.41 | 38.2 ± 17.77 |
MPA from aggregometry (turbidimetric) with 20 µM adenosine diphosphate.
| percentage of MPA | PPI Group 1: Regimen A | PPI Group 1: Regimen B | PPI Group 2: Regimen A | PPI Group 2: Regimen C | PPI Group 3: Regimen A | PPI Group 3: Regimen D | PPI Group 4: Regimen A | PPI Group 4: Regimen E |
|---|---|---|---|---|---|---|---|---|
| Pharmacodynamic Parameter MPA From Aggregometry (Turbidimetric) With 20 µM Adenosine Diphosphate. | 36.7 ± 9.11 | 41.6 ± 12.65 | 43.1 ± 13.24 | 46.3 ± 16.93 | 43.5 ± 14.00 | 53.5 ± 13.75 | 39.3 ± 13.22 | 47.9 ± 15.77 |
Collected over Treatment-emergent adverse events are adverse events that started or worsened after the first dose of study drug and within 30 days after the last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PPI Group 1: Regimen A | — | 0/40 (0%) | 13/39 (33.3%) |
| PPI Group 1: Regimen B | — | 0/40 (0%) | 16/39 (41%) |
| PPI Group 2: Regimen A | — | 0/40 (0%) | 19/39 (48.7%) |
| PPI Group 2: Regimen C | — | 1/40 (2.5%) | 16/38 (42.1%) |
| PPI Group 3: Regimen A | — | 0/40 (0%) | 14/40 (35%) |
| PPI Group 3: Regimen D | — | 0/40 (0%) | 11/38 (28.9%) |
| PPI Group 4: Regimen A | — | 0/40 (0%) | 17/39 (43.6%) |
| PPI Group 4: Regimen E | — | 0/40 (0%) | 15/39 (38.5%) |
| Event | PPI Group 1: Regimen A | PPI Group 1: Regimen B | PPI Group 2: Regimen A | PPI Group 2: Regimen C | PPI Group 3: Regimen A | PPI Group 3: Regimen D | PPI Group 4: Regimen A | PPI Group 4: Regimen E |
|---|---|---|---|---|---|---|---|---|
| Serum sickness-like reactionInvestigations | 0/40 | 0/40 | 0/40 | 1/40 | 0/40 | 0/40 | 0/40 | 0/40 |
| Event | PPI Group 1: Regimen A | PPI Group 1: Regimen B | PPI Group 2: Regimen A | PPI Group 2: Regimen C | PPI Group 3: Regimen A | PPI Group 3: Regimen D | PPI Group 4: Regimen A | PPI Group 4: Regimen E |
|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 3/39 | 4/39 | 5/39 | 7/38 | 2/40 | 6/38 | 6/39 | 4/39 |
| NauseaGastrointestinal disorders | 3/39 | 3/39 | 5/39 | 1/38 | 1/40 | 0/38 | 0/39 | 1/39 |
| PruritusSkin and subcutaneous tissue disorders | 1/39 | 0/39 | 4/39 | 0/38 | 1/40 | 0/38 | 1/39 | 0/39 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/39 | 0/39 | 0/39 | 1/38 | 1/40 | 0/38 | 0/39 | 4/39 |
| EcchymosisSkin and subcutaneous tissue disorders | 3/39 | 1/39 | 3/39 | 3/38 | 4/40 | 2/38 | 2/39 | 0/39 |
| DizzinessNervous system disorders | 1/39 | 1/39 | 0/39 | 3/38 | 1/40 | 0/38 | 2/39 | 2/39 |
| Back painMusculoskeletal and connective tissue disorders | 3/39 | 1/39 | 0/39 | 1/38 | 2/40 | 1/38 | 2/39 | 0/39 |
| Abdominal pain lowerGastrointestinal disorders | 0/39 | 0/39 | 1/39 | 2/38 | 1/40 | 1/38 | 3/39 | 0/39 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/39 | 0/39 | 2/39 | 1/38 | 2/40 | 0/38 | 3/39 | 2/39 |
| Abdominal painGastrointestinal disorders | 0/39 | 1/39 | 0/39 | 2/38 | 2/40 | 1/38 | 3/39 | 1/39 |
| Age Continuous(years) | PPI Group 1 | PPI Group 2 | PPI Group 3 | PPI Group 4 | Total |
|---|---|---|---|---|---|
| Mean | 32.8 ± 6.48 | 35.7 ± 7.92 | 34.0 ± 7.40 | 33.3 ± 7.10 | 33.9 ± 7.26 |
| Sex: Female, Male(Participants) | PPI Group 1 | PPI Group 2 | PPI Group 3 | PPI Group 4 | Total |
|---|---|---|---|---|---|
| Female | 20 | 20 | 20 | 20 | 80 |
| Male | 20 | 20 | 20 | 20 | 80 |
The record gives a start of Dec 2009, a primary completion of Jun 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2011, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Clopidogrel · Lansoprazole · Dexlansoprazole · Omeprazole · Esomeprazole